Nasdaq

Shattuck Labs Advances SL-325 Program with IND Filing Anticipated by Q3 2025, Reports Q1 Financial Results

Shattuck Labs, Inc. has announced progress in its SL-325 program, with an Investigational New Drug (IND) filing expected in the third quarter of 2025. The company reported a cash balance of ...
Business Insider

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of ...

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic ...
Nasdaq

Northstrive Biosciences Receives FDA Feedback Supporting IND Filing for EL-22 in Obesity Treatment

Northstrive Biosciences has received preliminary feedback from the FDA on its nonclinical studies and clinical plans for its product, EL-22, intended for use alongside GLP-1 receptor agonists in ...
Hosted on MSN

FibroBiologics files IND application to initiate clinical trials of CYPS317

FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking regulatory clearance to initiate clinical trials of ...
Business Insider

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...